Symbols

PLX

Protalix·AMEX

--(--)

PLX fundamentals

PLX Q4 2025 Earnings

Protalix (PLX) released its earnings on Mar 18, 2026: revenue was 9.12M (YoY -49.92%), missed estimates; EPS was -0.06 (YoY -160.00%), missed estimates.

Revenue / YoY

9.12M

-49.92%

EPS / YoY

-0.06

-160.00%

Report date

Mar 18, 2026

PLX Earnings Call Summary for Q4,2025

$25M Milestone Boosts Liquidity: EU approval of Elfabrio q4w regimen triggers $25M payment, projecting $50M cash balance by April 2026.
Revenue Growth Accelerates: 2026 revenue expected to grow >50% to $78-83 million, driven by Chiesi's expanding Fabry patient base.
Pipeline Progress: PRX-115 gout trial enrolling; PRX-119 renal candidate advancing with Q2 updates. Fabry market projected to $3.4B by 2030.
Strategic Focus: Shifting revenue mix to high-margin Chiesi partnership while investing in best-in-class rare disease therapies.

Earnings

EPS

Revenue

Revenue & Expenses

PLX has released its 2025 Q4 earnings report, with revenue of 9.12M, reflecting a YoY change of -49.93%, and net profit of -5.50M, showing a YoY change of -184.76%. The Sankey diagram below clearly presents PLX's revenue sources and cost distribution.

Key Indicators

Protalix (PLX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Protalix (PLX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Protalix (PLX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Protalix (PLX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown